BioLineRx has been granted a patent for a method of treating cancer in humans. The method involves administering a CXCR4 antagonistic peptide and an immune-check point regulator, such as a PD1 antagonist, to the subject. The patent also covers the use of other immune-check point regulators and chemotherapeutic agents in combination with the peptide. This patent provides a potential new treatment option for cancer patients. GlobalData’s report on BioLineRx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioLineRx, peptide pharmacophores was a key innovation area identified from patents. BioLineRx's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11648293B2) discloses a method for treating cancer in humans. The method involves three steps: administering a peptide with a specific amino acid sequence, administering a PD1 antagonist, and administering a chemotherapeutic agent. These three components work together to effectively treat the cancer in the human subject.
The patent specifically mentions that the method can be used for treating pancreatic cancer, a particularly aggressive and difficult-to-treat form of cancer. This highlights the potential significance of the method in addressing a specific type of cancer that has limited treatment options.
Furthermore, the patent specifies that the PD1 antagonist used in the method is an anti-PD1 antibody. PD1 antagonists are a type of immunotherapy that target the PD1 protein, which is involved in suppressing the immune response against cancer cells. By using an anti-PD1 antibody, the method aims to enhance the immune response against the cancer cells, potentially leading to improved treatment outcomes.
In addition, the patent emphasizes that when the method is applied to pancreatic cancer, the specific peptide with the amino acid sequence mentioned in SEQ ID NO: 1 is used in conjunction with the anti-PD1 antibody. This suggests that the combination of the peptide, PD1 antagonist, and chemotherapeutic agent may have a synergistic effect in treating pancreatic cancer.
Overall, this granted patent presents a method for treating cancer, specifically pancreatic cancer, by combining a peptide, a PD1 antagonist (anti-PD1 antibody), and a chemotherapeutic agent. The method holds potential for improving treatment outcomes in patients with pancreatic cancer, a challenging disease to manage. Further research and clinical trials may be necessary to validate the effectiveness and safety of this method in treating cancer in humans.
To know more about GlobalData’s detailed insights on BioLineRx, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
